Godrej Properties Gets Buy Call From IDBI Capital IDBI Capital Technical and Derivative Research Head Brijesh Ali suggested a 'Buy' for the stock. The target price for the stock is Rs 2,416, which implied a 8.1% upside from Friday's close price. The stop loss is at Rs 2,179.Out of 20 analysts tracking the company, 16 maintain a 'buy' rating, one recommends a 'hold,' and one suggests to 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 24.9%Dr. Reddy's LaboratoriesMahesh Ojha of Hensex Securities Pvt. suggested to book profit on this stock. There's no more triggers on sight for further upside. Fourth-quarter earnings were not that great. According to Ojha, one can book 50% profit at current price level range. Dr Reddy's Gets Two Observations From US FDA For New York API PlantApollo Hospitals, AstraZeneca, Infosys, Vodafone Idea Shares In Focus Apollo Hospitals Enterprise Ltd., AstraZeneca Pharma Ltd., Infosys Ltd., and Vodafone Idea Ltd. shares will likely be in focus because of the news flow and fourth-quarter earnings.Stock Market Highlights: Benchmarks Log Second Weekly Decline As Nifty Slips Below 24,800. Read more on Markets by NDTV Profit.